Skip to content
Screener

Revvity RVTY Life Sciences — Segment research and development expenses

Similar metrics at other companies

Ashland logo
ASHLife Sciences — Research And Development Expense
$4M0.0%
Thermo Fisher Scientific logo
TMOLife Sciences Solutions — Research and development expenses
$131M-5.8%
Agilent Technologies logo
ALife Sciences and Diagnostics Markets — Research and Development Expense
$64M+8.5%
GLW
GLWLife Sciences and Emerging Growth Businesses — Research, development and engineering expenses
$27M+3.8%
Beam Therapeutics logo
BEAMExternal Research And Development Expenses — Research And Development Expense
$30.08M-12.6%
Momentus logo
MNTSReportable Segment — Research and development expenses
$4.17M+118%

Other financials

Income statement

See full
Revenue$711.1M+7.0%
Gross profit$387.7M+3.2%
Operating income$75.9M+5.1%
Net income$40.7M-3.6%
EPS (diluted)$0.36+2.9%

Balance sheet

See full
Cash & equivalents$861.5M-24.3%
Total debt$3.9B+17.8%
Total equity$7.2B-5.9%
Total assets$12.0B-2.9%

Cash flow

See full
Operating cash flow$115.2M-10.1%
CapEx$19.8M+23.7%
Free cash flow$95.5M-14.9%

Valuation

See full
Market cap$12.83B+28.7%
Enterprise value$15.91B+28.6%
P/E53.5×+18.6×
P/S4.4×+0.9×

Profitability

See full
Gross margin48.5%
Operating margin12.4%-1.1pp
Net margin8.3%-2.1pp
FCF margin17%-1.9pp

Returns & leverage

See full
Return on equity3.2%-0.5pp
Debt / equity0.5×+0.1×
Current ratio1.7×-1.9×

Where this comes from

Reported directly by Revvity in its filing.

Tagged under the XBRL concept revv:SegmentResearchAndDevelopmentExpenses.

The source filing: Revvity’s 10-Q, filed May 12, 2026.

Filed
May 12, 2026, 4:07 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0000031791-26-000019
Line itemApril 5, 2026 / Life SciencesApril 5, 2026 / DiagnosticsApril 5, 2026 / TotalMarch 30, 2025 / Life SciencesMarch 30, 2025 / DiagnosticsMarch 30, 2025 / Total
Segment revenue$361,845$349,273$711,118$340,395$324,367$664,762
Segment cost of revenue131,574156,753119,321135,190
Segment selling, general and administrative expenses94,66890,19287,09489,891
Segment research and development expenses31,62426,20628,26925,271
Segment operating income$103,979$76,122180,101$105,711$74,015179,726
Corporate expenses(12,247)(9,815)
Amortization of intangible assets(85,081)(82,700)
Purchase accounting adjustments(141)177

Item 1.Unaudited Financial Statements

FAQ

What is Revvity's life sciences — segment research and development expenses?
Revvity (RVTY) reported life sciences — segment research and development expenses of $31.62M in Q1 2026.
How has Revvity's life sciences — segment research and development expenses changed year-over-year?
Revvity's life sciences — segment research and development expenses increased by 11.9% year-over-year, from $28.27M to $31.62M.
What is the long-term trend for Revvity's life sciences — segment research and development expenses?
Over 3 years (2022 to 2025), Revvity's life sciences — segment research and development expenses has grown at a 8.4% compound annual growth rate (CAGR), from $87.86M to $112.03M.
What does life sciences — segment research and development expenses mean?
Expenditures dedicated to the discovery, development, and improvement of products and technologies within the Life Sciences segment. This reflects the company's commitment to innovation and long-term pipeline growth.

Ask your AI about Revvity's life sciences — segment research and development expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude